109173 ⎘
Structure or type of the nucleic acid; Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
Antisense oligonucleotide compositions
#602GUIDE RNA WITH CHEMICAL MODIFICATIONS
#603Modulators of PCSK9 expression
#604PHARMACEUTICAL COMPOSITION
#605Oligonucleotides for modulating TMEM106B expression
#606Oligomers and oligomer conjugates
#607Compositions and methods for facilitating delivery of synthetic nucleic acids to cells
#608Modified oligonucleotides and methods of use
#609Compounds and methods for the modulation of amyloid-β precursor protein
#610COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION
#611COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN
#612Inhibitors of micro-RNA 22
#613Micro-RNA and obesity
#614Modified double-stranded RNA agents
#615Modified compounds and uses thereof
#616COMPOSITIONS AND METHODS FOR NEXT GENERATION SEQUENCING
#617Methods and compositions for modulating apolipoprotein (a) expression
#618Selective antisense compounds and uses thereof
#619Genome editing using effector oligonucleotides for therapeutic treatment
#620COMPOUNDS OF CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE THEREOF
#621ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
#622MODULATORS OF DNM2 EXPRESSION
#623Conjugated antisense compounds and their use
#624METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
#625Short interfering nucleic acid (siNA) compositions
#626Oligomeric compounds comprising bicyclic nucleotides and uses thereof
#627Compositions and methods for treatment of cardiac diseases
#628Antisense oligonucleotides targeting ATXN3
#629Anti-C9ORF72 oligonucleotides and related methods
#630Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
#631MODULATION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT3) EXPRESSION
#632OLIGONUCLEOTIDES FOR MODULATING FNDC3B EXPRESSION
#633Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression
#634Antisense oligonucleotides targeting alpha-synuclein and uses thereof
#635Therapeutic targeting of a microRNA to treat Duchenne muscular dystrophy
#636Compositions for modulating SOD-1 expression
#637Antisense oligonucleotides targeting alpha-synuclein and uses thereof
#638RNA-Guided Targeting of Genetic and Epigenomic Regulatory Proteins to Specific Genomic Loci
#639Oligonucleotides for inducing paternal UBE3A expression
#640ASSAYS AND METHODS FOR DETERMINING EXPRESSION OF THE LECT2 GENE
#641Treatment of HER-2 dependent cancer using an agent that modulates the activity of a miRNA
#642OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE
#643GAPMER OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE
#644CANCER BIOMARKERS AND METHODS OF USE
#645Compositions and methods for modulating Ataxin 3 expression
#646METHODS FOR THE PRODUCTION OF STERILE FISH AND OTHER EGG-PRODUCING AQUATIC ANIMALS AND COMPOUNDS FOR USE IN THE METHODS
#647Bivalent Nucleic Acid Ligands and Uses Therefor
#648Compositions and their uses directed to huntingtin
#649CANCER TREATMENT
#650LNA-G process
#651STEREODEFINED SUB-MOTIF OPTIMISATION METHODS
#652TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
#653MicroRNA Compounds and Methods for Modulating MIR-21 Activity
#654Oligonucleotide comprising an inosine for treating DMD
#655Gapmers and methods of using the same for the treatment of muscular dystrophy
#656Exosomal loading using hydrophobically modified oligonucleotides
#657Splice Switching Oligomers for TNF Superfamily Receptors and Their Use in Treatment of Disease
#658Oligonucleotide inhibiting the expression of Chop
#659MicroRNA inhibitor therapy in systemic lupus erythematosus
#660ANTISENSE COMPOUNDS
#661Dynamic pharmacokinetic-modifying anchors
#662CHANNEL MODULATORS
#663Oligonucleotide sequences targeting transcription factor TSC22D4 for the treatment of insulin resistance
#664POLYNUCLEOTIDE AGENTS TARGETING PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) AND METHODS OF USE THEREOF
#665Antisense oligomers targeting PCSK9
#666Methods and compositions using RNA interference and antisense oligonucleotides for inhibition of KRAS
#667Oligonucleotides for reduction of PD-L1 expression
#668Antisense oligonucleotide and composition for prevention or treatment of glycogen storage disease type Ia
#669Channel modulators
#670Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA
#671Compositions for modulating expression of C9ORF72 antisense transcript
#672Pan-genotypic agents against influenza virus and methods of using the same
#673Methods for treatment of polycystic kidney disease
#674Immunosuppression-reverting oligonucleotides inhibiting the expression of CD39
#675COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION
#676Antisense Compounds and Uses Thereof
#677ANTISENSE OLIGONUCLEOTIDES FOR MODULATING RELA EXPRESSION
#678ALLELE SELECTIVE INHIBITION OF MUTANT C9ORF72 FOCI EXPRESSION BY DUPLEX RNAS TARGETING THE EXPANDED HEXANUCLEOTIDE REPEAT
#679Modulators of IRF5 expression
#680LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#681Allele-specific therapy for Huntington disease haplotypes
#682tRNA derived small RNAs (tsRNAs) involved in cell viability
#683Polycomb-Associated Non-Coding RNAs
#684Modulators of PCSK9 expression
#685COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION
#686MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION
#687Modulators of FOXP3 expression
#688Compositions and methods for detecting and treating insulin resistance
#689Modified Oligonucleotides for Treatment of Polycystic Kidney Disease
#690Multiplex Guide RNAS
#691COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS
#692ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
#693Modulating RNA Interactions with Polycomb Repressive Complex 1 (PRC1)
#694Antisense therapies for treating cancer
#695METHODS AND COMPOSITIONS FOR MODULATING ALPHA-1-ANTITRYPSIN EXPRESSION
#696MODULATORS OF COMPLEMENT FACTOR B
#697Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection
#698COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH GAIN-OF-FUNCTION MUTATIONS IN KCNT1
#699Compositions and methods for modulating growth hormone receptor expression
#700NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
#701Modulation of angiopoietin-like 3 expression
#702LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#703Methods of reducing expression of x-inactivation escapee genes and autosomal genes
#704POLYNUCLEOTIDE AGENTS TARGETING SERPINC1 (AT3) AND METHODS OF USE THEREOF
#705Methods for controlling seizures by manipulating the levels of microRNA-211 (miR-211) in the brain
#706Methods and compositions for managing vascular conditions
#707MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPODYSTROPHY POPULATIONS
#708Compositions for modulating Ataxin 2 expression
#709Therapeutic agent for treating cancer comprising anti-miRNA-albumin composite
#710MicroRNA inhibitor
#711Allele specific modulators of P23H rhodopsin
#712Engineered target specific base editors
#713Oligonucleotides for inducing paternal UBE3A expression
#714SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF
#715Oligonucleotides for reduction of PD-L1 expression
#716Compositions for modulating SOD-1 expression
#717Compositions and methods for modulating SMN gene family expression
#718Methods and pharmaceutical compositions for the treatment of cystic fibrosis
#719Technique for treating cancer using structurally-reinforced S-TuD
#720Oligomers and oligomer conjugates
#721Oligonucleotides for modulating ATXN2 expression
#722Targeting human satellite II (HSATII)
#723Arrays of memory cells individually comprising a capacitor and an elevationally-extending transistor, methods of forming a tier of an array of memory cells, and methods of forming an array of memory cells individually comprising a capacitor and an elevationally-extending transistor
#724Oligonucleotides for modulating Tau expression
#725Antisense oligonucleotides for inhibition of PD-L1 expression and treating cancer
#726Methods and compositions of short small hairpin RNAs and microRNAs for wound healing
#727Methods of selecting therapeutic molecules
#728ANTISENSE COMPOUNDS TARGETING GENES ASSOCIATED WITH FIBRONECTIN
#729MODIFIED CRISPR RNA AND USES THEREOF
#730Anti-IL-17 aptamer having improved retention in blood
#731siRNA sequence-independent modification formats for reducing off-target phenotypic effects in RNAI, and stabilized forms thereof
#732Antisense oligonucleotides that inhibit influenza virus replication and uses thereof
#733ANTISENSE OLIGONUCLEOTIDES FOR MODULATING NFKB1 EXPRESSION
#734Compositions for modulating C9ORF72 expression
#735Conjugated antisense compounds and their use
#736OLIGONUCLEOTIDES FOR MODULATING ATXN2 EXPRESSION
#737Modulators of APOL1 expression
#738OLIGONUCLEOTIDE COMPOSITIONS AND USES THEREOF
#739Oligomeric compounds comprising α-β-constrained nucleic acid
#740ANTISENSE OLIGONUCLEOTIDES FOR MODULATING RELB EXPRESSION
#741ANTISENSE OLIGONUCLEOTIDES FOR MODULATING NFKB2 EXPRESSION
#742METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
#743Bicyclic nucleosides and oligomers prepared therefrom
#744Modulation of Lnc05 expression
#745Artificial exosome composition and related methods
#746MODULATION OF TMPRSS6 EXPRESSION
#747ANTISENSE OLIGONUCLEOTIDES FOR MODULATING REL EXPRESSION
#748SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF
#749ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND USES THEREOF
#750Double-stranded nucleic acid inhibitor molecules modified with Tm-increasing nucleotides
#751ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS
#752Oligonucleotides for inducing paternal UBE3A expression
#753Antisense compounds targeting Leucine-Rich repeat kinase 2(LRRK2) for the treatment of Parkinsons disease
#754Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
#755Compounds and methods for enhanced cellular uptake
#756CCCTC-binding factor (CTCF) RNA interactome
#757Soluble TNF Receptors and Their Use in Treatment of Disease
#7585′S-LNA nucleotides and oligonucleotides
#759MICRORNAS IN NEURODEGENERATIVE DISORDERS
#760Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression
#761CAMK2D antisense oligonucleotides and uses thereof
#762Chimeric double-stranded nucleic acid
#763Therapeutic targeting of a microRNA to treat Duchenne muscular dystrophy
#764Compositions for delivery of cargo to cells
#765COMPOSITIONS FOR DELIVERY OF CARGO TO CELLS
#766Inhibiting microRNA to prevent development of essential hypertension
#767Compositions for modulating C9ORF72 expression
#768TGF-beta oligonucleotide for use in treatment of ophthalmic diseases
#769Antisense oligomers targeting HOXB-AS3 long non-coding RNA
#770Compositions and methods for treatment of cardiac diseases
#771Modulators of DNM2 expression
#772MOLECULAR RE-ENGINEERING OF EXCITATION-INHIBITION BALANCE IN MEMORY CIRCUITS
#773Modified double-stranded RNA agents
#774Modified double-stranded RNA agents
#775Modulation of prekallikrein (PKK) expression
#776RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#777MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE
#778Mixed tricyclo-DNA, 2′-modified RNA oligonucleotide compositions and uses thereof
#779Neutral nanotransporters
#780RNA PRODUCTS AND USES THEREOF
#781Carboxylated 2′-amino-LNA nucleotides and oligonucleotides comprising the same
#782Modulators of vault RNAs for use in the treatment of diseases
#783Antisense-induced exon exclusion in type VII collagen
#784MIR-92 INHIBITORS AND USES THEREOF
#785RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
#786RNA modulating oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophy
#787Tuning CRISPR/Cas9 activity with chemically modified nucleotide substitutions
#788OLIGOMERIC COMPOUNDS COMPRISING BICYCLIC NUCLEOTIDES AND USES THEREOF
#789Reduced size self-delivering RNAI compounds
#790Targeting MicroRNAs for Metabolic Disorders
#791Methods for treatment of polycystic kidney disease
#792Allele-specific gene suppression
#793MODIFIED TGF-BETA OLIGONUCLEOTIDE FOR USE IN A METHOD OF PREVENTING AND/OR TREATING AN OPHTHALMIC DISEASE
#794MicroRNA Compounds and Methods for Modulating MIR-122
#795Modulating the cellular stress response
#796Pan-genotypic agents against influenza virus and methods of using the same
#797LNCRNA MEG3 for therapy and diagnosis of cardiac remodelling
#798Arrays of memory cells individually comprising a capacitor and an elevationally-extending transistor, methods of forming a tier of an array of memory cells, and methods of forming an array of memory cells individually comprising a capacitor and an elevationally-extending transistor
#799GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof
#800MIR-29 MIMICS AND USES THEREOF
#801Modulation of adipose tissue macrophage phenotype by use of MicroRNA-30
#802Methods and compositions for managing vascular conditions using miR-483 mimics and HIF1alpha pathway inhibitors
#803Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
#804Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection
#805Oligonucleotide compositions and uses thereof
#806RNA nanoparticles for brain tumor treatment
#807Oligonucleotides for treating expanded repeat diseases
#808Methods and means for efficient skipping of at least one of the following exons of the human Duchenne muscular dystrophy gene: 43, 46, 50-53
#809Compositions and methods for treating diabetic retinopathy
#8105′-cyclo-phosphonate modified nucleotides
#811Multiplex detection of short nucleic acids
#812DOWNREGULATING MIR-132 FOR THE TREATMENT OF LIPID RELATED DISORDERS
#813Polynucleotides containing a morpholino linker
#814Methods of modulating KEAP1
#815Pharmaceutical Composition
#816COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF CANCER USING SLNCR ISOFORMS
#817Modulation of angiopoietin-like 3 expression
#818RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#819Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#820Multimeric oligonucleotide compounds
#821Methods and compositions for inhibiting PMP22 expression
#822Nucleic acid-polypeptide compositions and uses thereof
#823Nucleic acid-polypeptide compositions and uses thereof
#824Approach for treating inflammatory disorders
#825ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
#826COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION
#827LNA-G Process
#828MODULATORS OF COMPLEMENT FACTOR B
#829Methods for reactivating genes on the inactive X chromosome
#830PLANT GENOME MODIFICATION USING GUIDE RNA/CAS ENDONUCLEASE SYSTEMS AND METHODS OF USE
#831TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
#832In vitro toxicity screening assay
#833Methods for performing multiplexed real-time PCR in a self-contained nucleic acid analysis pouch
#834Polynucleotide agents targeting factor XII (hageman factor) (F12) and methods of use thereof
#835Treatment of filaggrin (FLG) related diseases by modulation of FLG expression and activity
#836Oligonucleotides
#837Splice Switching Oligomers for TNF Superfamily Receptors and Their Use in Treatment of Disease
#838Methods for modulating Ataxin 2 expression
#839Compositions and methods for modulating angiopoietin-like 3 expression
#840RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
#841α-synuclein expression inhibitor
#842Anti-ADAM33 oligonucleotides and related methods
#843SELECTIVE REDUCTION OF ALLELIC VARIANTS
#844COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA
#845Nucleic acid-polypeptide compositions and uses thereof
#846PLANT GENOME MODIFICATION USING GUIDE RNA/CAS ENDONUCLEASE SYSTEMS AND METHODS OF USE
#847Nucleic acid-polypeptide compositions and uses thereof
#848Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
#849Methods for reducing LRRK2 expression
#850Methods and compositions for managing vascular conditions
#851RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
#852RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Duchenne and Becker Muscular Dystrophy
#853MicroRNA Compounds and Methods for Modulating MIR-21 Activity
#854Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
#855Cancer treatment
#856Methods of reducing expression of X-inactivation escapee genes and autosomal genes
#857Compositions and their uses directed to huntingtin
#858Antitumor drug delivery formulation
#859RNA interference in skin indications
#860COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION
#861Chimeric double-stranded nucleic acid
#862RNA interactome of polycomb repressive complex 1 (PRC1)
#863Methods of treatment using antisense oligomers and conjugates targeting PCSK9
#864Manufacture of antisense oligomers and conjugates targeting PCSK9
#865COMPOUNDS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION FOR IMPROVING A DIABETIC PROFILE
#866Nanoparticle formulations for delivery of nucleic acid complexes
#867MicroRNA Compounds and Methods for Modulating MIR-21 Activity
#868Targeting MicroRNAs for the Treatment of Fibrosis
#869Linkage modified oligomeric compounds
#870COMPOSITIONS AND METHODS FOR MODULATING SMN GENE FAMILY EXPRESSION
#871Oligonucleotides for modulating gene expression and uses thereof
#872Compositions and methods for modulating apolipoprotein (a) expression
#873Compositions and methods for modulating apolipoprotein C-III expression
#874Compositions and their uses directed to huntingtin
#875Oligonucleotide-based inhibitors comprising locked nucleic acid motif
#876Modulation of SMN expression
#877MODULATORS OF KRAS EXPRESSION
#878Compositions and methods for modulating Ataxin 3 expression
#879Conjugated antisense compounds and their use
#880Targeting microRNAs for metabolic disorders
#881Oligonucleotide conjugates
#882Oligomeric compounds comprising bicyclic nucleotides and uses thereof
#883RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
#884Polycomb-associated non-coding RNAs
#885Methods and compositions of short small hairpin RNAS and microRNAS for wound healing
#886UNA oligomers for therapeutics with prolonged stability
#887MiR-92 inhibitors and uses thereof
#888ANTISENSE DESIGN
#889ANTISENSE DESIGN
#890Methods and compositions for modlating apolipoprotein (A) expression
#891Modified TGF-beta oligonucleotides
#892Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
#893METHODS FOR TREATING TUMORS
#894METHODS AND COMPOSITIONS FOR MODULATING ALPHA-1-ANTITRYPSIN EXPRESSION
#895NUCLEIC ACID COMPLEX HAVING AT LEAST ONE BULGE STRUCTURE
#896Modulation of TMPRSS6 expression
#897Compositions and methods for modulating MECP2 expression
#898Structurally-enhanced miRNA inhibitor S-TuD
#899THERAPEUTIC OLIGONUCLEOTIDES
#900Antisense oligomers targeting PCSK9